OraSure Technologies - OSUR Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OSUR shares.
View OSUR analyst ratings or view top-rated stocks.

2 brokers have issued 12-month price objectives for OraSure Technologies' shares. Their OSUR share price forecasts range from $10.00 to $14.00. On average, they expect the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 227.9% from the stock's current price.
View analysts price targets for OSUR or view top-rated stocks among Wall Street analysts.

OraSure Technologies' stock was trading at $8.69 at the beginning of the year. Since then, OSUR shares have decreased by 57.9% and is now trading at $3.66.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our OSUR earnings forecast.

OraSure Technologies, Inc. (NASDAQ:OSUR) issued its quarterly earnings results on Tuesday, August, 9th. The medical instruments supplier reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.12. The medical instruments supplier earned $80.23 million during the quarter, compared to analysts' expectations of $69.91 million. OraSure Technologies had a negative trailing twelve-month return on equity of 12.92% and a negative net margin of 24.18%. The firm's revenue for the quarter was up 39.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.02) EPS.

OraSure Technologies issued an update on its third quarter 2022 earnings guidance on Tuesday, September, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $90.00 million-$95.00 million, compared to the consensus revenue estimate of $76.15 million.

2 employees have rated OraSure Technologies Chief Executive Officer Stephen Tang on Glassdoor.com. Stephen Tang has an approval rating of 100% among the company's employees. This puts Stephen Tang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), Energy Transfer (ET), XOMA (XOMA), Overstock.com (OSTK), Ford Motor (F), Pfizer (PFE), Abbott Laboratories (ABT), Advanced Micro Devices (AMD) and Activision Blizzard (ATVI).

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

OraSure Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (4.74%), Renaissance Technologies LLC (3.32%), Kennedy Capital Management Inc. (1.55%), Primecap Management Co. CA (1.26%), Wells Fargo & Company MN (1.20%) and Northern Trust Corp (1.05%). Insiders that own company stock include Michael Celano, Nancy J Gagliano and Ronny B Lancaster.
View institutional ownership trends.

Shares of OSUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OSUR stock can currently be purchased for approximately $3.66.

OraSure Technologies (NASDAQ:OSUR) has a market capitalization of $265.79 million and generates $233.67 million in revenue each year. The medical instruments supplier earns $-23,000,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

The company employs 785 workers across the globe.

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The official website for the company is www.orasure.com. The medical instruments supplier can be reached via phone at (610) 882-1820, via email at investorinfo@orasure.com, or via fax at 610-882-1830.